Peer-reviewed veterinary case report
Monitoring dog Cushing's disease treatment using blood proteins
By Arteaga, A et al.·Published in The Journal of small animal practice·2010·Faculty of Veterinary Medicine, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Monitoring the response of canine hyperadrenocorticism to trilostane treatment by assessment of acute phase protein concentrations.
- Species:
- dog
Plain-English summary
A 7-year-old Beagle was diagnosed with hyperadrenocorticism (Cushing's disease) and started on trilostane treatment. After treatment, the dog's blood tests showed significant improvements in certain markers, indicating better control of the disease. Specifically, levels of haptoglobin, alkaline phosphatase, and cholesterol decreased, suggesting the treatment was effective. However, other markers like C-reactive protein did not change significantly, indicating they might not be useful for monitoring the disease. Overall, the trilostane helped manage the dog's condition, but the standard ACTH stimulation test remains the best way to assess treatment success.
People also search for: dog Cushing's disease treatment · Beagle hyperadrenocorticism symptoms · trilostane effectiveness in dogs
Abstract
BACKGROUND: Acute phase proteins (APPS) include haptoglobin (Hp), C-reactive protein (CRP) and serum amyloid A (SAA). Increased Hp concentrations may be induced by endogenous or exogenous glucocorticoids in dogs. OBJECTIVES: To assess whether control of hyperadrenocorticism (HAC) affects the concentrations of Hp, CRP, SAA, alkaline phosphatase (ALKP) and cholesterol, to determine whether these analytes can be used to assess control of HAC following trilostane treatment, and whether a combination of these tests offers a valid method of assessing disease control. METHODS: Hp, CRP, SAA, ALKP and cholesterol were assessed in 11 dogs with spontaneous HAC before and after treatment with trilostane. Adequate control of HAC was defined as post-ACTH cortisol less than 150 nmol/l. RESULTS: Significant reductions in Hp, ALKP, cholesterol and SAA (P<0.05) but not of CRP were found after control of HAC. Only Hp, cholesterol and ALKP were moderately informative (Se & Sp>0.7) of disease control when compared to adrenocorticotropin or corticotropin (ACTH) stimulation test. SAA and CRP were unhelpful (Se & Sp<0.7). The analysis of the combination of the analytes did not improve the correlation with ACTH stimulation test. CLINICAL RELEVANCE: Relying on these analytes does not provide additional information over ACTH stimulation test results when assessing control of HAC treated with trilostane.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/20406368/